certificate of analysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Medium-velocity: Between 360 m/s (1,200 ft/s) and 600 m/s (2,000 ft/s) These are more typical of shotgun blasts or higher caliber handguns like magnums. The risk of infection from these types of wounds can vary depending on the type and pattern of bullets fired as well as the distance from the firearm.
With the news of fission neutrons from uranium fission, Szilárd immediately understood the possibility of a nuclear chain reaction using uranium. In the summer, Fermi and Szilard proposed the idea of a nuclear reactor (pile) to mediate this process. The pile would use natural uranium as fuel. Fermi had shown much earlier that neutrons were far more effectively captured by atoms if they were of low energy (so-called "slow" or "thermal" neutrons), because for quantum reasons it made the atoms look like much larger targets to the neutrons. Thus to slow down the secondary neutrons released by the fissioning uranium nuclei, Fermi and Szilard proposed a graphite "moderator", against which the fast, high-energy secondary neutrons would collide, effectively slowing them down. With enough uranium, and with sufficiently pure graphite, their "pile" could theoretically sustain a slow-neutron chain reaction. This would result in the production of heat, as well as the creation of radioactive fission products. In August 1939, Szilard, Teller and Wigner thought that the Germans might make use of the fission chain reaction and were spurred to attempt to attract the attention of the United States government to the issue. Towards this, they persuaded Albert Einstein to lend his name to a letter directed to President Franklin Roosevelt. On 11 October, the Einstein–Szilárd letter was delivered via Alexander Sachs.
Many allergens, such as dust or pollen, are airborne particles. In these cases, symptoms arise in areas exposed to air, such as the eyes, nose, and lungs. For instance, allergic rhinitis, also known as hay fever, irritates the nose, sneezing, itching, and redness of the eyes. Inhaled allergens can also lead to increased production of mucus in the lungs, shortness of breath, coughing, and wheezing. Allergic rhinitis can simultaneously occur with other allergic responses such as asthma. Aside from these ambient allergens, allergic reactions can result from foods, insect stings, and reactions to medications like aspirin and antibiotics such as penicillin. Symptoms of food allergy include abdominal pain, bloating, vomiting, diarrhea, itchy skin, and hives. Food allergies rarely cause respiratory (asthmatic) reactions, or rhinitis. Insect stings, food, antibiotics, and certain medicines may produce a systemic allergic response that is also called anaphylaxis; multiple organ systems can be affected, including the digestive system, the respiratory system, and the circulatory system. Depending on the severity, anaphylaxis can include skin reactions, bronchoconstriction, swelling, low blood pressure, coma, and death. This type of reaction can be triggered suddenly or have a delayed onset. The anaphylactic reaction may seem to subside, but may recur over time.
Hydrogen halides and their solutions: hydrofluoric acid (HF), hydrochloric acid (HCl), hydrobromic acid (HBr), hydroiodic acid (HI) Halogen oxoacids: hypochlorous acid (HClO), chlorous acid (HClO2), chloric acid (HClO3), perchloric acid (HClO4), and corresponding analogs for bromine and iodine Hypofluorous acid (HFO), the only known oxoacid for fluorine. Sulfuric acid (H2SO4) Fluorosulfuric acid (HSO3F) Nitric acid (HNO3) Phosphoric acid (H3PO4) Fluoroantimonic acid (HSbF6) Fluoroboric acid (HBF4) Hexafluorophosphoric acid (HPF6) Chromic acid (H2CrO4) Boric acid (H3BO3) A sulfonic acid has the general formula RS(=O)2–OH, where R is an organic radical. Methanesulfonic acid (or mesylic acid, CH3SO3H) Ethanesulfonic acid (or esylic acid, CH3CH2SO3H) Benzenesulfonic acid (or besylic acid, C6H5SO3H) p-Toluenesulfonic acid (or tosylic acid, CH3C6H4SO3H) Trifluoromethanesulfonic acid (or triflic acid, CF3SO3H) Polystyrene sulfonic acid (sulfonated polystyrene, [CH2CH(C6H4)SO3H]n)
Sources: en.wikipedia.org
== Signs and symptoms == People with antidepressant discontinuation syndrome have been on an antidepressant for at least four weeks and have recently stopped taking the medication, whether abruptly, after a fast taper, or each time the medication is reduced on a slow taper. Commonly reported symptoms include flu-like symptoms (e.g., nausea, vomiting, diarrhea, headaches, sweating) and sleep disturbances (e.g., insomnia, nightmares, constant sleepiness). Sensory and movement disturbances have also been reported, including imbalance, tremors, vertigo, dizziness, and electric-shock-like experiences in the brain, often described by people who have them as brain zaps. These "brain zaps" have been described as an electric shock felt in the skull, potentially triggered by lateral eye movement, and at times accompanied by vertigo, pain, or dissociative symptoms. Some individuals consider it as a pleasant experience akin to an orgasm, however it is more often reported as an unpleasant experience that interferes with daily function. Mood disturbances such as dysphoria, anxiety, or agitation are also reported, as are cognitive disturbances such as confusion and hyperarousal. In cases associated with sudden discontinuation of MAO inhibitors (MAOIs), acute psychosis has been observed. Over fifty symptoms have been reported. The SNRI venlafaxine has been reported to have a higher incidence in withdrawal symptoms after discontinuation when compared to other SNRIs. Venlafaxine has also been implicated to create withdrawal symptoms regardless of dosage.
Taha Othman Ishaq (or Osman), a lawyer and member of the FFC negotiating committee, declined his nomination by the FFC to the Sovereignty Council on the grounds that the FFC alliance had earlier agreed that members of the negotiating committee should not become members of the Sovereignty Council. Raja Nicola was the civilian member of the Sovereignty Council mutually chosen by the FFC and TMC. The choice of Nicola, as a member of the Sudanese Copt community, is seen as a symbol of respect for diversity, in particular to Sudanese Christians. On 4 February 2021, al-Burhan issued a decree to add three new members to the Council. The new members are Sudanese Revolutionary Front leader El Hadi Idris Yahya, Sudan People's Liberation Movement-North leader Malik Agar, and Sudan Liberation Movement for Justice-Karbino leader El Tahrir Abubakr Hajar.
===== Electrode ===== In 2010, researchers first reported creating a graphene-silicon heterojunction solar cell, where graphene served as a transparent electrode and introduced a built-in electric field near the interface between the graphene and n-type silicon to help collect charge carriers. In 2012 researchers reported efficiency of 8.6% for a prototype consisting of a silicon wafer coated with trifluoromethanesulfonyl-amide (TFSA) doped graphene. Doping increased efficiency to 9.6% in 2013. In 2015 researchers reported efficiency of 15.6% by choosing the optimal oxide thickness on the silicon. This combination of carbon materials with traditional silicon semiconductors to fabricate solar cells has been a promising field of carbon science. In 2013, another team reported 15.6% percent by combining titanium oxide and graphene as a charge collector and perovskite as a sunlight absorber. The device is manufacturable at temperatures under 150 °C (302 °F) using solution-based deposition. This lowers production costs and offers the potential using flexible plastics. In 2015, researchers developed a prototype cell that used semitransparent perovskite with graphene electrodes. The design allowed light to be absorbed from both sides. It offered efficiency of around 12 percent with estimated production costs of less than $0.06/watt. The graphene was coated with PEDOT:PSS conductive polymer (polythiophene) polystyrene sulfonate). Multilayering graphene via CVD created transparent electrodes reducing sheet resistance.
=== Books === Kierkegaard: Construction of the Aesthetic (1933) Dialectic of Enlightenment (with Max Horkheimer, 1944) Composing for the Films (1947) Philosophy of New Music (1949) The Authoritarian Personality (1950) Minima Moralia: Reflections from Damaged Life (1951) In Search of Wagner (1952) Prisms (1955) Against Epistemology: A Metacritique; Studies in Husserl and the Phenomenological Antinomies (1956) Dissonanzen. Musik in der verwalteten Welt (1956) Notes to Literature I (1958) Sound Figures (1959) Mahler: A Musical Physiognomy (1960) Notes to Literature II (1961) Introduction to the Sociology of Music (1962) Hegel: Three Studies (1963) Critical Models: Interventions and Catchwords (1963) Quasi una Fantasia (1963) The Jargon of Authenticity (1964) Night Music: Essays on Music 1928–1962 (1964) Negative Dialectics (1966) Alban Berg: Master of the Smallest Link (1968) Critical Models: Interventions and Catchwords (1969) Posthumously published
==== Uric acid ==== Uric acid has the highest concentration of any blood antioxidant and provides over half of the total antioxidant capacity of human serum. Uric acid's antioxidant activities are also complex, given that it does not react with some oxidants, such as superoxide, but does act against peroxynitrite, peroxides, and hypochlorous acid. Concerns over elevated UA's contribution to gout must be considered one of many risk factors. By itself, UA-related risk of gout at high levels (415–530 μmol/L) is only 0.5% per year with an increase to 4.5% per year at UA supersaturation levels (535+ μmol/L). Many of these aforementioned studies determined UA's antioxidant actions within normal physiological levels, and some found antioxidant activity at levels as high as 285 μmol/L.
Sources: en.wikipedia.org
Finasteride, also known as 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one, is a synthetic androstane steroid and 4-azasteroid. It is an analogue of androgen steroid hormones like testosterone and DHT. As an unconjugated steroid, finasteride is a highly lipophilic compound.
Lamont Bentley (October 25, 1973 – January 19, 2005) was an American actor and rapper best known for his role as Hakeem Campbell on the UPN sitcom Moesha. Bentley was also known for his role as Crazy K in the 1995 horror film Tales from the Hood and C-Money in the 2001 film The Wash featuring Dr. Dre and Snoop Dogg.
All our advice to the commander in chief [went] through the chief of our section, who was a career civil servant. His guiding principle was to tell the commander in chief things that the commander in chief liked to hear... To push the idea of ripping out gun turrets, against the official mythology of the gallant gunner defending his crew mates... was not the kind of suggestion the commander in chief liked to hear. On hearing the news of the bombing of Hiroshima:
=== Defence arguments === Letby's defence argued that she was a dedicated nurse working within a system that had failed, and that the prosecution's case relied on assumptions of deliberate harm combined with her presence during certain incidents. They contended that shortcomings in staffing and care on the neonatal unit were extensive and could not reasonably be attributed to a single individual. The defence also suggested that "extraordinary bleeding" in one infant might have been caused by medical equipment rather than deliberate injury. Counsel for the defence maintained that the prosecution had not presented sufficient evidence to support its theories of how the infants were harmed. They argued that the evidence for air embolism was too weak to sustain the allegation and noted that the term did not appear in Letby's internet search history. No independent medical experts were called by the defence. The only defence witness other than Letby was a plumber who testified that the unit had recurring plumbing problems, including sewage backing up into sinks, which he said required frequent call‑outs. The defence suggested that such hygiene issues could have contributed to the unit's elevated mortality rate. In later reporting, Dewi Evans acknowledged that pseudomonas had been detected in the unit's water supply, leading to several cases of pneumonia.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.